Clinical Study Results
Part 2
Group number Treatment given
7 (1 participant with surface • 0.005 mg MEDI9197 every 28 days
tumors)
Part 3
Group number Treatment given
8 (3 participants with • 0.012 mg MEDI9197 every 28 days
surface tumors)
• 1500 mg durvalumab
9 (6 participants with deep • 0.012 mg MEDI9197 every 28 days
tumors)
• 1500 mg durvalumab
10 (2 participants with deep • 0.012 mg MEDI9197 every 28 days
tumors)
• 1500 mg durvalumab
• Radiation therapy
11 (6 participants with • 0.005 mg of MEDI9197 every 28 days
surface tumors)
• 1500 mg durvalumab
4